Life Sciences

Federal regulators released a letter that accuses Framingham-based HeartWare International of design and software malfunctions that might have resulted in serious injuries and death.

Marlborough biotech firm Advanced Cell Technology said it has picked up $30 million in capital through a common stock purchase agreement with a Chicago-based investment firm. The deal, with Lincoln Park Capital Fund, gives Advanced Cell (ACT) another funding option to grow its business “without creating complications in our capital structure” as the company pushes for long-term, “fundamental-based institutional capital.” interim president, CEO and COO Ted Myles said in a statement.

RXi Pharmaceuticals announced it will officially open its new office and laboratory in the Marlborough Technology Center on July 9.

Karyopharm Therapeutics, the Natick-based biotechnology startup that's developing new cancer treatments for people and animals, is relocating its corporate headquarters to Newton. The company, which launched a successful IPO in the fall, will leave Natick at the end of July and will not have a significant presence in Natick following the move, according to Paul Brannelly, senior vice president of finance and administration at Karyopharm.

Natick-based Karyopharm Therapeutics said underwriters have exercised their option to purchase nearly 400,000 additional stock shares, boosting total offering proceeds to $120.9 million.

The federal government has given the go-ahead for a Marlborough company to market its wearable robotic exoskeleton for individuals with spinal cord injuries, the company said.

Karyopharm Therapeutics has launched a public offering of 2.2 million shares of its common stock as it seeks to generate $77 million in capital.

Natick-based Karyopharm Therapeutics, a clinical-stage company that is developing treatments for cancer and other major diseases, said it has initiated a Phase-2 study of its KPT-330 compound, known as Selinexor, in patients with acute myeloid leukemia (AML).

Advanced Cell Technology (ACT), a Marlborough-based biotechnology firm that is developing stem cell treatments for diseases causing blindness, has hired an industry veteran as its new president and CEO.

Northeastern University's Dukakis Center for Urban & Regional Policy released new data Wednesday showing that the Bay State leads the nation in life sciences on a population basis.